Table 1.

Characteristics of 200 enrolled subjects

Hemophilia A, N (%)Hemophilia B, N (%)Total, N (%)
Severe disease (FA < 1%)* 79 (64.2) 32 (41.6) 111 (55.5) 
Moderate disease (FA 1-5%) 44 (35.8) 45 (58.4) 89 (44.5) 
Race: white/African American/other 106 (86.2)/17 (13.8)/0 71 (92.2)/4 (5.2)/2 (2.6) 177 (88.5)/21 (10.5)/2 (1) 
Hispanic ethnicity 5 (4.1) 5 (6.5) 10 (5) 
Mean/median age, years 61/60 61/61 61/60 
Use of prophylaxis 42 (34.2) 19 (24.7) 61 (30.5) 
Current inhibitor 8 (6.5) 1 (1.3) 9 (4.5) 
HCV*, 85 (69.1) 39 (50.7) 124 (62) 
HBV*, 6 (4.9) 2 (2.6) 8 (4) 
HIV* 46 (37.4) 8 (10.4) 54 (27) 
Hemophilia A, N (%)Hemophilia B, N (%)Total, N (%)
Severe disease (FA < 1%)* 79 (64.2) 32 (41.6) 111 (55.5) 
Moderate disease (FA 1-5%) 44 (35.8) 45 (58.4) 89 (44.5) 
Race: white/African American/other 106 (86.2)/17 (13.8)/0 71 (92.2)/4 (5.2)/2 (2.6) 177 (88.5)/21 (10.5)/2 (1) 
Hispanic ethnicity 5 (4.1) 5 (6.5) 10 (5) 
Mean/median age, years 61/60 61/61 61/60 
Use of prophylaxis 42 (34.2) 19 (24.7) 61 (30.5) 
Current inhibitor 8 (6.5) 1 (1.3) 9 (4.5) 
HCV*, 85 (69.1) 39 (50.7) 124 (62) 
HBV*, 6 (4.9) 2 (2.6) 8 (4) 
HIV* 46 (37.4) 8 (10.4) 54 (27) 

FA, factor activity.

*

Statistically significant differences between hemophilia A and B: severity, P = .002; HCV infection, P = .009; HIV infection, P < .001.

Includes those with active and treated infections.

Includes those with HBV surface antigen and/or DNA positivity.

or Create an Account

Close Modal
Close Modal